Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
Kaddoura M, Wiedmeier-Nutor J, Gupta V, Ziccheddu B, Shivaram S, Tang H, Fonseca R, Durante M, Matulis S, Jelinek T, Landgren O, Mitsiades C, Bergsagel P, Braggio E, Boise L, Fonseca R, Kumar S, Maura F, Baughn L. Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax. Blood 2024, 144: 249. DOI: 10.1182/blood-2024-204071.Peer-Reviewed Original ResearchProgression free survivalSingle nucleotide variantsWhole-genome sequencingMultiple myelomaMM patientsFocal deletionsCopy number variantsMechanisms of resistanceTraining cohortValidation cohortChronic lymphocytic leukemia treated with venetoclaxDisease progressionMAPK pathwayMedian progression free survivalPopulation of MM patientsDeterminants of clinical outcomeAnti-CD38 agentsTreated with venetoclaxComprehensive genomic profilingMAPK pathway mutationsStructural variantsAcute myeloid leukemiaGenomic eventsLoss of NoxaNovel drug combinations